CD8A and neoplasm: Thus, we further unraveled the role of CD4+ T cells engineered with the CD8-restricted PTPRZ11814-1822 TCR on tumor cell lysis in vitro through enriching CD4+ and CD8+ T cells via magnetic-activated cell sorting (MACS) post transduction (Fig. 3h, Supplementary Fig. 6g, h).